Cytogel Pharma
PrivateLast Round
VC Round
Apr 29, 2026
Total Funding Raised
$1.8M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cytogel Pharma is a clinical-stage biopharmaceutical company that develops first-in-class drug candidates from the novel endomorphin family of molecules to target key pain pathways and alleviate pain.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cytogel Pharma Comparables
Compare Cytogel Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Latigo Biotherapeutics | 83% | |
| Neumentum, Inc. | 81% | |
| Tafalgie Therapeutics | 80% |
Cytogel Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Apr 29, 2026 | ||||
| Early Funding | Nov 20, 2025 | ||||
| Debt | Oct 14, 2025 | ||||
| VC Round | Jun 10, 2023 | ||||
| Debt | Jun 15, 2022 | ||||
VC Round | Sep 27, 2019 |
Cytogel Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Centripetal Capital Partners | VC Round |
| U.S. Government | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 33% MoM, from 652 to 864.
- Jul 25, 2026
Monthly visitors increased 2315% MoM, from 27 to 652.
Recent news
Latest coverage and updates
- is_developingOct 13, 2026
Cytogel Pharma develops CYT-1010 for moderate-to-severe acute postoperative pain, with its Phase 2 clinical trial underway in Connecticut on Oct 13th '26 and results expected in Q1 '27.
Cytogel Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cytogel Pharma's valuation, stock price, and market status.
Is Cytogel Pharma a public or private company?
Cytogel Pharma is a private company.
What is the current stock price of Cytogel Pharma?
Cytogel Pharma is a private company, so its shares have no public market price. Caplight tracks Cytogel Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cytogel Pharma worth (valuation)?
Valuation information for Cytogel Pharma is not publicly available.
Can I buy Cytogel Pharma stock?
Cytogel Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cytogel Pharma's last funding round?
Cytogel Pharma's most recent funding round was VC Round on April 29, 2026.
Who are the main investors in Cytogel Pharma?
Key investors in Cytogel Pharma include Centripetal Capital Partners, U.S. Government.
Will Cytogel Pharma IPO soon?
No public IPO plans have been announced for Cytogel Pharma.
How can I track Cytogel Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Cytogel Pharma's shares on secondary markets.